Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF) (2021 - 2026)

Amylyx Pharmaceuticals' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 50.0% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $400000.0, a 50.0% decrease from a year earlier, with the FY2025 full-year figure at $500000.0, down 44.44% from the prior year.
• Depreciation & Amortization (CF) steadied at $100000.0 in Q1 2026 per AMLX's latest filing, from $100000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $302000.0 in Q3 2023 and bottomed at $35000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $200000.0 (2024), against an average of $180882.4.
• Across the five-year window, Depreciation & Amortization (CF) jumped 1550.0% in 2022 and sank 50.0% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then sank by 33.55% to $200000.0 in 2024, then sank by 50.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
• Per Business Quant, the three latest AMLX Depreciation & Amortization (CF) figures stand at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025).